retatrutide clinical trials phase 3 dosage Eli Lilly's data is in on Retatrutide! Here's what they found Eli Lilly retatrutide Phase 3

We will explain the program to you in full, and provide you with a prescription for a GLP-1 agonist if it is appropriate

When people stop taking the new generation of weight-loss drugs, they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday

Tirzepatide (Zepbound) FDA-indicated for obesity and sleep apnea A dual GLP-1/GIP receptor agonist

, Reimann, F

As a phase 2 trial, the study was not designed to assess long-term durability, rare adverse events, or cardiovascular outcomes

For cash-pay patients, PlushCare now has more relevance than it did earlier in 2026 because its doctors can prescribe into newer direct-pay pathways: Wegovy cash-pay pathway: from $199/month intro pricing for the first two months at lower doses through NovoCare, then $399/month for maintenance